Molecular Determinants of Multi-nucleoside Analogue Resistance in HIV-1 Reverse Transcriptases Containing a Dipeptide Insertion in the Fingers Subdomain
暂无分享,去创建一个
Sandra Franco | Luis Menéndez-Arias | S. Franco | L. Menéndez-Arias | Tania Matamoros | Blanca M Vázquez-Alvarez | Antonio Mas | Miguel Angel Martínez | A. Mas | M. Martínez | Tania Matamoros
[1] F. Brun-Vézinet,et al. Switch to Unusual Amino Acids at Codon 215 of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene in Seroconvertors Infected with Zidovudine-Resistant Variants , 1998, Journal of Virology.
[2] E. Domingo,et al. Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. , 2000, Virus research.
[3] Kamalendra Singh,et al. Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. , 2002, Biochemistry.
[4] J Desmyter,et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. , 1988, Journal of virological methods.
[5] Bikram Chakraborty,et al. Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation , 2002, Journal of Virology.
[6] A. Mian,et al. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. , 1999, Molecular cell.
[7] R. D. de Boer,et al. Establishment of New Transmissible and Drug-Sensitive Human Immunodeficiency Virus Type 1 Wild Types due to Transmission of Nucleoside Analogue-Resistant Virus , 2001, Journal of Virology.
[8] T. Merigan,et al. Genotypic, Phenotypic, and Modeling Studies of a Deletion in the β3-β4 Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Gene That Is Associated with Resistance to Nucleoside Reverse Transcriptase Inhibitors , 2000, Journal of Virology.
[9] S. Sharma,et al. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. , 1997, Biochemistry.
[10] K. Anderson,et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. , 2003, Biochemistry.
[11] S. Swaminathan,et al. Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations , 2004, Antimicrobial Agents and Chemotherapy.
[12] Colombe Chappey,et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. , 2003, The Journal of infectious diseases.
[13] A. D. Clark,et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[14] R. Schooley,et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.
[15] E. De Clercq,et al. Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues , 2000, Antimicrobial Agents and Chemotherapy.
[16] L. Menéndez-Arias. Targeting HIV: antiretroviral therapy and development of drug resistance. , 2002, Trends in pharmacological sciences.
[17] R de Boer,et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215 , 1997, Journal of virology.
[18] B. Larder,et al. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. , 1994, The Journal of general virology.
[19] L. Naeger,et al. ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2002, Antimicrobial Agents and Chemotherapy.
[20] B. Larder,et al. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.
[21] D. Katzenstein,et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. , 1998, The Journal of clinical investigation.
[22] R. D. de Boer,et al. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. , 2001, AIDS research and human retroviruses.
[23] D. I. Stuart,et al. Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215 , 2002, Journal of Virology.
[24] T. Merigan,et al. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years , 1997, Antimicrobial agents and chemotherapy.
[25] E. Arnold,et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[26] B. Marchand,et al. Site-specific Footprinting Reveals Differences in the Translocation Status of HIV-1 Reverse Transcriptase , 2003, Journal of Biological Chemistry.
[27] D. Stuart,et al. 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] S. Sarafianos,et al. Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase , 2001, Journal of Virology.
[29] B. Larder,et al. Effects of Dipeptide Insertions between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain Elongation , 2003, Journal of Virology.
[30] Miguel Ángel Martínez,et al. Role of a dipeptide insertion between codons 69 and 70 of HIV‐1 reverse transcriptase in the mechanism of AZT resistance , 2000, The EMBO journal.
[31] E. Domingo,et al. Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. , 1997, Nucleic acids research.
[32] R. Schinazi,et al. Differential Removal of Thymidine Nucleotide Analogues from Blocked DNA Chains by Human Immunodeficiency Virus Reverse Transcriptase in the Presence of Physiological Concentrations of 2′-Deoxynucleoside Triphosphates , 2000, Antimicrobial Agents and Chemotherapy.
[33] A. So,et al. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Fantini,et al. Stable rearrangements of the β3–β4 hairpin loop of HIV‐1 reverse transcriptase in plasma viruses from patients receiving combination therapy , 1998, AIDS.
[35] M. Parniak,et al. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. , 1998, Biochemistry.
[36] C. M. Joyce,et al. Deoxynucleoside Triphosphate and Pyrophosphate Binding Sites in the Catalytically Competent Ternary Complex for the Polymerase Reaction Catalyzed by DNA Polymerase I (Klenow Fragment) (*) , 1995, The Journal of Biological Chemistry.
[37] G L Verdine,et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.
[38] E. Domingo,et al. Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. , 1996, The EMBO journal.
[39] J. Erickson,et al. Structural mechanisms of HIV drug resistance. , 1996, Annual review of pharmacology and toxicology.
[40] A. D. Clark,et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. , 1998, Journal of molecular biology.
[41] W. Rozenbaum,et al. Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[42] A. D. Clark,et al. Structures of HIV‐1 reverse transcriptase with pre‐ and post‐translocation AZTMP‐terminated DNA , 2002, The EMBO journal.
[43] Miguel Ángel Martínez,et al. Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. , 1999, Journal of molecular biology.
[44] B. Larder,et al. Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates , 2002, Antimicrobial Agents and Chemotherapy.
[45] S. Sarafianos,et al. Nucleoside Analog Resistance Caused by Insertions in the Fingers of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involves ATP-Mediated Excision , 2002, Journal of Virology.
[46] V. Calvez,et al. Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors , 2001, Antimicrobial Agents and Chemotherapy.
[47] L. Menéndez-Arias,et al. Coupling Ribose Selection to Fidelity of DNA Synthesis , 2000, The Journal of Biological Chemistry.
[48] J. Mellors,et al. Relationship between 3′-Azido-3′-Deoxythymidine Resistance and Primer Unblocking Activity in Foscarnet-Resistant Mutants of Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2003, Journal of Virology.
[49] T. Merigan,et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.
[50] E. Domingo,et al. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. , 2002, Journal of molecular biology.
[51] D. Stuart,et al. A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance , 1999, Antimicrobial Agents and Chemotherapy.
[52] N. Sluis-Cremer,et al. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) , 2000, Cellular and Molecular Life Sciences (CMLS).
[53] W. Heneine,et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Stammers,et al. Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine , 2001, Antimicrobial Agents and Chemotherapy.
[55] J. Mellors,et al. Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 2002, Antimicrobial Agents and Chemotherapy.
[56] P. Massip,et al. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine , 1999, Journal of medical virology.
[57] E. De Clercq,et al. The HIV‐1 Reverse Transcription (RT) Process as Target for RT Inhibitors , 2000, Medicinal research reviews.
[58] B. Canard,et al. Nucleotide Analogue Binding, Catalysis and Primer Unblocking in the Mechanisms of HIV-1 Reverse Transcriptase-Mediated Resistance to Nucleoside Analogues , 2002, Antiviral therapy.
[59] L. Naeger,et al. Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication , 2000, Antiviral therapy.